Complement Component C3A
The complement system is a group of proteins (complement components) that compose a part of the immune system. Once activated, the components of the system act in a cascade, activating one complement component after the next until the target is damaged or destroyed. Quantitative measurement of complement components aids in the diagnosis of immunologic disorders. Complement component C3 (C3) is synthesized in the liver and is part of the complement system. It is the most abundant complement protein, comprising 70% of the total system, is an acute phase reactant, and attacks and kills any microorganisms or threats to the body. C3 is produced when inflammatory responses develop. Increased levels are found during inflammatory processes. It is elevated in systemic infections and noninfectious chronic inflammatory conditions. Decreased C3 levels indicate complement component activation. Other reasons for decreased values of C3 include the genetic condition homozygous C3 deficiency as well as numerous inflammatory and infectious diseases. Common causes for decreased C3 are systemic lupus erythematosus (SLE), rheumatoid arthritis, parasitic infections, and bacterial sepsis. Recurrent bacterial infections are common in patients with low C3 levels. Measuring C4 along with C3 is common. C4 is also an activation complement component and in its absence, C3 will not be able to function properly. C4 is also decreased in systemic lupus erythematosus (SLE), rheumatoid arthritis, and other autoimmune disorders.
- As an aid in diagnosis of recurrent microbial infections, angioedema, or inflammation
- As an aid in diagnosis of chronic hepatitis C
- As an aid in diagnosis and monitoring the activity of acute or chronic autoimmune diseases such as systemic lupus erythematosus
- As an aid in diagnosis and monitoring immune complex-related diseases and conditions such as: glomerulonephritis, serum sickness, rheumatoid arthritis, and vasculitis
- Diagnosis of Complement Component C3 congenital deficiency
Increased in:
- Many inflammatory conditions
- Systematic infections (sepsis)
- Neoplasms and cancer
- Viral hepatitis
- Myocardial infarction
- Sarcoidosis
- Amyloidosis
- Diabetes mellitus
- Pregnancy
Decreased in:
- Decreased synthesis (liver disease)
- Protein malnutrition
- Congenital deficiency
- Severe liver disease
- Membranoproliferative glomerulonephritis
- Systemic lupus erythematosus (SLE)
- Sjögren’s syndrome
- Rheumatoid arthritis
- Disseminated intravascular coagulation (DIC)
- Paroxysmal nocturnal hemoglobinuria
- Autoimmune hemolytic anemia
- Increased loss in burns and gastroenteropathies
- Gastrectomy
64 – 166 mg/dL
Serum (SST).
Stability
- Ambient: 72 hours
- Refrigerated: 7 days
- Frozen: 30 days
- Serum should be separated immediately from clot. Overnight fasting preferred.
- Ann N Y Acad Sci. 2009 Sep;1173:108-23. [PMID: 19758139]
- Ann Med Interne (Paris). 2003 Dec;154(8):529-40. [PMID: 15037829]
- Biochem Soc Trans. 2004 Feb;32(Pt 1):21-7. [PMID: 14748705]
- N Engl J Med. 1987;316:1525. [PMID: 3295544]
- Intern Med. 2001;40:1254. [PMID: 11813855]
- Curr Rheumatol Rep. 2004;6:375. [PMID: 15355750]
- Curr Opin Pediatr. 1998 Dec;10(6):600-6. [PMID: 9848020]
- Pediatr Clin North Am. 2000 Dec;47(6):1339-54. [PMID: 11130999]
- J Allergy Clin Immunol. 2004 Apr;113(4):585-93. [PMID: 15100659]
- Burtis C, Ashwood E, and Bruns D. Fundamentals of Clinical Chemistry. St. Louis: Saunders (2008).